Acadia drops major add-on indication for psychosis drug after pivotal miss

Acadia tumbles 19% after dropping pursuit of major depressive disorder claim for pimavanserin

Acadia shed nearly $1.7 billion in market cap on Tuesday after saying it would no longer pursue the broader population of major depressive disorder patients for its psychosis drug after a Phase III miss.

Pimavanserin missed the primary endpoint in the

Read the full 416 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE